These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20822073)

  • 1. Avoiding infusion therapy prime benefit of new MS drug.
    Morrow T
    Manag Care; 2010 Aug; 19(8):49-50. PubMed ID: 20822073
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging disease-modifying oral therapies for multiple sclerosis.
    Losy J; Kalinowska-Łyszczarz A
    J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].
    Chiba K; Kataoka H
    Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):24-5. PubMed ID: 18421849
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral fingolimod (gilenya) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
    [No Abstract]   [Full Text] [Related]  

  • 5. [Emerging treatments for multiple sclerosis].
    Nau JY
    Rev Med Suisse; 2010 Jun; 6(251):1162-3. PubMed ID: 20572362
    [No Abstract]   [Full Text] [Related]  

  • 6. Fingolimod. Mitsubishi Pharma/Novartis.
    Dumont FJ
    IDrugs; 2005 Mar; 8(3):236-53. PubMed ID: 15772896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis poses tough drug development challenges.
    Senior K
    Drug Discov Today; 2005 Dec; 10(23-24):1583-4. PubMed ID: 16376813
    [No Abstract]   [Full Text] [Related]  

  • 8. Trial watch: Phase III promise for oral multiple sclerosis therapy.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180099
    [No Abstract]   [Full Text] [Related]  

  • 9. The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived.
    Weissert R
    Expert Rev Neurother; 2006 Nov; 6(11):1587-90. PubMed ID: 17144774
    [No Abstract]   [Full Text] [Related]  

  • 10. FTY720 and central memory: out of sight, out of mind.
    Slavin AJ; Zamvil SS
    Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831
    [No Abstract]   [Full Text] [Related]  

  • 11. Fingolimod for multiple sclerosis.
    Pelletier D; Hafler DA
    N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
    [No Abstract]   [Full Text] [Related]  

  • 12. FTY720 for cancer therapy (Review).
    Zhang L; Wang HD; Ji XJ; Cong ZX; Zhu JH; Zhou Y
    Oncol Rep; 2013 Dec; 30(6):2571-8. PubMed ID: 24100923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed fingolimod-associated asystole.
    Espinosa PS; Berger JR
    Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
    Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V
    Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New disease-modifying and symptomatic therapies for multiple sclerosis].
    Weise G; Buttmann M
    MMW Fortschr Med; 2012 Apr; 154(7):64-6. PubMed ID: 22558878
    [No Abstract]   [Full Text] [Related]  

  • 16. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
    Hecht B
    Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumefactive multiple sclerosis lesions under fingolimod treatment.
    Visser F; Wattjes MP; Pouwels PJ; Linssen WH; van Oosten BW
    Neurology; 2012 Nov; 79(19):2000-3. PubMed ID: 23035065
    [No Abstract]   [Full Text] [Related]  

  • 18. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
    Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
    Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agency is under fire for refusing to supply details of sudden deaths after first dose of multiple sclerosis drug.
    Wise J
    BMJ; 2012 Feb; 344():e1360. PubMed ID: 22362460
    [No Abstract]   [Full Text] [Related]  

  • 20. Infections cast cloud over Novartis' MS therapy.
    Garber K
    Nat Biotechnol; 2008 Aug; 26(8):844-5. PubMed ID: 18688218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.